Skip to main content

Advertisement

SpringerLink
Log in

Epidemiologic and Clinical Implications of Second-Generation Pneumococcal Conjugate Vaccines

  • RESPIRATORY INFECTIONS (F ARNOLD, SECTION EDITOR)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

This review is based on published literature about some of the potential advantages and challenges of the second generation of pneumococcal conjugate vaccines, with special reference to 13-valent vaccine in children and adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Jit M. The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis. J Infect. 2010;61(2):114–24. A good review and meta-analyisis including 63 original articles involving 3,408 meningitis survivors during the years 1991–2009.

    Article  PubMed  Google Scholar 

  2. • O’Brien KL, Wolfson LJ, Watt JP, et al. Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. A country-specific review about the incidence of invasive disease and deaths in children younger than 5 years performed by the HIB and pneumococcal global burden of disease study team.

    Article  PubMed  Google Scholar 

  3. McEllistrem MC, Adams JM, Patel K, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2005;40:1738–44.

    Article  PubMed  Google Scholar 

  4. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86:408–16.

    Article  PubMed  Google Scholar 

  5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642–50.

    Article  PubMed  Google Scholar 

  6. Hausdorff P, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet. 2005;5:83–93.

    Google Scholar 

  7. Centers for Disease Control and Prevention (CDC). Recommendations of the immunization practices advisory committee (ACIP) update: pneumococcal polysaccharide vaccine usage – United States. MMWR Morb Mortal Wkly Rep. 1984;33:273–6.

    Google Scholar 

  8. de Roux A, Schmöle-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46(7):1015–23.

    Article  PubMed  Google Scholar 

  9. Black S, Shinefield H, Fireman B. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187–95.

    Article  PubMed  CAS  Google Scholar 

  10. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810–5.

    Article  PubMed  Google Scholar 

  11. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10–6.

    Article  PubMed  Google Scholar 

  12. Pilishvili T, Lexau C, Farley MM, et al. Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.

    Article  PubMed  Google Scholar 

  13. Rückinger S, van der Linden M, Reinert RR, et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine. 2009;27(31):4136–41.

    Article  PubMed  Google Scholar 

  14. Hanquet G, Lernout T, Vergison A, et al. Belgian IPD Scientific Committee. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine. 2011;29(16):2856–64.

    Article  PubMed  Google Scholar 

  15. Ingels H, Rasmussen J, Andersen PH, et al. Danish Pneumococcal Surveillance Collaboration Group 2009-2010. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine. 2012;30(26):3944–50.

    Article  PubMed  Google Scholar 

  16. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784–92.

    Article  PubMed  CAS  Google Scholar 

  17. Muñoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174–82.

    Article  PubMed  Google Scholar 

  18. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298(15):1772–8.

    Article  PubMed  CAS  Google Scholar 

  19. Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122–40.

    Article  PubMed  CAS  Google Scholar 

  20. de Sevilla MF, García-García JJ, Esteva C, et al. Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine. Pediatr Infect Dis J. 2012;31(2):124–8.

    Article  PubMed  Google Scholar 

  21. Obando I, Muñoz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis. 2008;14(9):1390–7.

    Article  PubMed  Google Scholar 

  22. Thomas MF, Sheppard CL, Guiver M, et al. Emergence of pneumococcal 19A empyema in UK children. Arch Dis Child.2012. Oct 16. Epub ahead of print.

  23. Strachan RE, Cornelius A, Gilbert GL, et al. Australian Research Network in Empyema. Bacterial causes of empyema in children, Australia, 2007-2009. Emerg Infect Dis. 2011;17(10):1839–45.

    Article  PubMed  CAS  Google Scholar 

  24. Byington CL, Hulten KG, Ampofo K, et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol. 2010;48(2):520–5.

    Article  PubMed  CAS  Google Scholar 

  25. WHO Publication. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine. 2012;30(32):4717–8.

    Article  Google Scholar 

  26. Chowdhury P, Balluz L, Town M, et al. Surveillance of certain health behaviors and conditions among states and selected local areas—Behavioral Risk Factor Surveillance System, United States, 2007. MMWR Surveill Summ. 2010;59:1–220.

    PubMed  Google Scholar 

  27. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–60.

    Article  PubMed  Google Scholar 

  28. Nuorti JP, Whitney CG. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1–18.

    PubMed  Google Scholar 

  29. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126(1):186–90.

    Article  Google Scholar 

  30. Scientific committee on vaccine preventable diseases Hong Kong. Recommendations on the use of 13-valent pneumococcal conjugate vaccine in the children immunization program. Accessed 20 October 2012 http://www.chp.gov.hk/files/pdf/briefing_for_hcw_by_dr_cbchow.pdf.

  31. Centers for Disease Control and Prevention (CDC). Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816–9.

    Google Scholar 

  32. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17(6):1017–26.

    Article  PubMed  CAS  Google Scholar 

  33. Vanderkooi OG, Scheifele DW, Girgenti D, et al. Canadian PCV13 Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72–7.

    Article  PubMed  Google Scholar 

  34. Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, et al. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J. 2012;31(4):392–9.

    Article  PubMed  Google Scholar 

  35. Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines. 2011;10(7):951–80.

    Article  PubMed  CAS  Google Scholar 

  36. Bryant-Genevier M, Khoie T, Lee L, Vaillancourt J. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee. Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) Accesed 20 October 2012 .http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM239495.pdf.

  37. Pneumococcal vaccine support. Accessed 19 October 2012 http://www.gavialliance.org/support/nvs/pneumococcal/.

  38. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf Accessed December 17, 2012.

  39. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10).

  40. • Singleton R, Wenger J, Klejka JA, et al. The 13-Valent Pneumococcal Conjugate Vaccine for Invasive Pneumococcal Disease in Alaska Native Children: Results of a Clinical Trial. Pediatr Infect Dis J. 2012 Sep 20. Epub ahead of print. A prelicensure open-label clinical trial in Alaskan native children to assess effectiveness of PCV-13 in reducing PCV13-caused IPD. Concomitant reduction of non-PCV-related IPD was also observed.

  41. Moore M, Link-Gelles R, Farley M, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, United States, 2010–11. Presented at 8th International Symposium on Pneumococci & Pneumococcal Diseases. March 13, 2012.

  42. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634–43.

    Article  PubMed  Google Scholar 

  43. Strutton DR, Farkouh RA, Rubin JL, et al. Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. BMC Infect Dis. 2012;12:175. doi:10.1186/1471-2334-12-175.

    Article  PubMed  Google Scholar 

  44. • Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127–31. A case control evaluation of effectiveness of PCV13-specific serotypes in children performed in the U.K. after 1 year of introduction of PCV13 in the national immunization schedule.

    Article  PubMed  CAS  Google Scholar 

  45. Hak E, Grobbee DE, Sanders EAM, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med. 2008;66(9):378–83.

    PubMed  CAS  Google Scholar 

  46. • Weycker D, Sato R, Strutton D, et al. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine. 2012;30(36):5437–44. A microsimulation model of costs of IPD and all-cause nonbacteraemic pneumonia in adults conducted in the U.S.

    Article  PubMed  Google Scholar 

  47. Kuhlmann A, Theidel U, Pletz MW, et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012;2:4.

    Article  PubMed  Google Scholar 

  48. Benito-Fernandez J, Raso SM, Pocheville-Gurutzeta I, et al. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque country of Spain. Pediatr Infect Dis J. 2007;26:667–71.

    Article  PubMed  Google Scholar 

  49. Herz AM, Greenhow TL, Alcantara J, et al. Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr Infect Dis J. 2006;25:293–300.

    Article  PubMed  Google Scholar 

  50. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet. 2005;365:1139–46.

    Article  PubMed  CAS  Google Scholar 

  51. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244–56.

    Article  PubMed  CAS  Google Scholar 

  52. Spencer DA, Close AJ, Simmister C, et al. Impact of the 13-valent pneumococcal vaccine on the incidence of paediatric empyema in the north of England. In: Abstracts book of the 29th Annual Meeting of the European Society of Paediatric Infectious Diseases. The Hague, Netherlands, June 7–11, 2011; abstr. no 637.

  53. Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis. 2012;54(12):1765–73.

    Article  PubMed  Google Scholar 

  54. Xu Q, Almudervar A, Casey JR, et al. Nasopharyngeal bacterial interactions in children. Emerg Infect Dis. 2012;18(11):1738–45.

    Article  PubMed  Google Scholar 

  55. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29(4):304–9.

    PubMed  Google Scholar 

  56. • van Gils EJM, Hak E, Veenhoven RH, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One. 2011;6:e20229. A randomised controlled trial on the effect of PCV7 on pneumococcal carriage and nasopharyngeal colonisation of S. aureus (secondary outcome) in healthy newborns up to 2 years of age before the implementation of PCV7 in the Dutch national immunisation programme.

    Article  PubMed  Google Scholar 

  57. Dukers-Muijrers NHTM, Stobberingh E, Beissert P et al. Nasal carriage of Streptococcus pneumoniae serotypes and Staphylococcus aureus in Streptococcus pneumoniae-vaccinated and non-vaccinated young children. Epidemiol Infect. 2012. Available on CJO 2012 doi:10.1017/S095026881200115X.

  58. Moore DP, Dagan R, Madhi SA. Respiratory viral and pneumococcal coinfection of the respiratory tract: implications of pneumococcal vaccination. Expert Rev Respir Med. 2012;6(4):451–65.

    Article  PubMed  CAS  Google Scholar 

  59. Launes C, de-Sevilla MF, Selva L, et al. Viral coinfection in children less than five years old with invasive pneumococcal disease. Pediatr Infect Dis J. 2012;31(6):650–3.

    Article  PubMed  Google Scholar 

  60. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205(3):401–11.

    Article  PubMed  CAS  Google Scholar 

  61. Yildirim I, Stevenson A, Hsu KK, et al. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods. Pediatr Infect Dis J. 2012;31(10):1016–21.

    PubMed  Google Scholar 

  62. Muñoz-Almagro C, Ciruela P, Esteva C, et al. Catalan study group of invasive pneumococcal disease. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect. 2011;63(2):151–62.

    Article  PubMed  Google Scholar 

  63. Gladstone RA, Jefferies JM, Faust SN, et al. Continued control of pneumococcal disease in the UK- the impact of vaccination. J Med Microbiol. 2011;60:1–8.

    Article  PubMed  CAS  Google Scholar 

  64. Healthy people 2020. 2020 topics and objectives. Immunization and infectious diseases Available at http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=23 Accesed 27 october 2012.

  65. Wilby KJ, Werry D. A review of the effect of immunization programs on antimicrobial utilization. Vaccine. 2012;30:6509–14.

    Article  PubMed  Google Scholar 

  66. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). In: Abstracts book of the 51st Interscience Congress on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20, 2011; abstr. no. G3-1709.

  67. Sá-Leão R, Nunes S, Brito-Avo A, et al. Changes in pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-care centre attendees in Portugal, a country with widespread use of the seven-valent pneumococcal conjugate vaccine. Clin Microbiol Infect. 2009;15:1002–7.

    Article  PubMed  Google Scholar 

  68. Fleming-Dutra K, Mbaeyi C, Link-Gelles R, et al. Streptococcus pneumoniae Serotype 15A in Psychiatric Unit, Rhode Island, US, 2010-2011. Emerg Infect Dis. 2012;18(11):1889–93.

    Article  PubMed  Google Scholar 

  69. Gladstone RA, Jefferies JM, Faust SN, et al. Pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Rev Vaccines. 2012;11(8):889–902.

    Article  PubMed  CAS  Google Scholar 

  70. • van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One. 2012;7(7):339150. A study of serotype-specific differences in clinical presentation of IPD, outcome, and impact in the quality of life in the context of the 7-, 10-, and 13-valent pneumococcal conjugate vaccines, using an electronic linked database in the U.K.

    Google Scholar 

  71. Principi N, Esposito S. Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza. Hum Vaccin. 2011;7:905–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Molecular Microbiology Department, University Hospital Sant Joan de Déu, Passeig Sant Joan de Déu, Esplugues, 08950, Barcelona, Spain

    Carmen Muñoz-Almagro

  2. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

    Adoracion Navarro-Torne

  3. Infectious Diseases and Clinical Research Unit. Idibell, Ciberes, Bellvitge Hospital and University of Barcelona, Feixa Llarga s/n, 08907L’Hospitalet, Barcelona, Spain

    Roman Pallares

Authors
  1. Carmen Muñoz-Almagro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adoracion Navarro-Torne
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roman Pallares
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Muñoz-Almagro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muñoz-Almagro, C., Navarro-Torne, A. & Pallares, R. Epidemiologic and Clinical Implications of Second-Generation Pneumococcal Conjugate Vaccines. Curr Infect Dis Rep 15, 184–190 (2013). https://doi.org/10.1007/s11908-013-0326-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-013-0326-4

Keywords

Search

Navigation